131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma

Cancer

Volumn 78, Issue 10, 1996, Pages 2184-2192

  Sisson, James C ^a,b   Giordano, Thomas J ^b   Jamadar, David A ^b   Kazerooni, Ella A ^b   Shapiro, Brahm ^a   Gross, Milton D ^a   Zempel, Shirley A ^a   Spaulding, Susan A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

indices of response; lung metastases; papillary thyroid carcinoma; radioiodine

Indexed keywords

IODINE 131;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CERVICAL LYMPH NODE; CHILD; FEMALE; FOLLOW UP; HUMAN; LUNG METASTASIS; LUNG SCINTISCANNING; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; CARCINOMA, PAPILLARY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS;

EID: 0029911377     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2184::AID-CNCR21>3.0.CO;2-U     Document Type: Article

References (34)

1. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050-8.
2. Cady B, Rossi R, An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947-53.
3. Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:685-718.
4. Schlumberger M, Tubiana M, DeVathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bond metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960-7.
5. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma." Am J Surg Pathol 1984; 8:655-68.
6. Carcangiu ML, Zampi G, Rosai J. Papillary thyroid carcinoma: a study of its many morphologic expressions and clinical correlates. Pathol Annu 1985;20 (Pt 1):1-44.
7. LiVolsi V. Papillary neoplasms of the thyroid. Pathologic and prognostic features. Am J Clin Pathol 1992; 97:426-34.
8. Leeper RD, Shimaoka K. Treatment of metastatic thyroid cancer. Endocrinol Metab Clin North Am 1980; 9:383-404.
9. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med 1988; 29:1790-4.
10. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid: a clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985; 55:805-28.
11. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57:323-7.
12. Glanzmann WH. Therapy of the metastasizing adenocarcinoma of the thyroid gland using 131-I: experiences with 103 patients from 1963 to 1977. Strahlenther Oncol 1979; 155:223-9.
13. Dewan SS, Sharma SM, Ganatra RD. Radioiodine in treatment of metastatic thyroid cancer, Int J Nucl Med Biol 1979; 6:213-4.
14. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli MA, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626-31.
15. Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger F, Bacourt F. Pulmonary metastases in differentiated thyroid carcinoma: study of 58 cases with implications for the primary tumor treatment. Cancer 1984; 53:982-92.
16. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488-92.
17. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28:1888-91.
18. 131I therapy in differentiated thyroid carcinoma. Cancer 1981; 47:664-71.
19. Vassilopoulou-Sellin R, Klein MJ, Smith TH, Samaan NA, Frankenthaler RA, Goepfert H, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993; 71:1348-52.
20. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988; 67:501-8.
21. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995; 80:2041-5.
22. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309:937-41.
23. Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33:1132-6.
24. Koral KF, Adler RS, Carey JE, Beierwaltes WH. Iodine-131 treatment of thyroid cancer: absorbed dose calculated from post-therapy scans. J Nucl Med 1986; 27:1207-11.
25. O'Connell MEA, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol 1993; 28:16-26.
26. Samuel AM, Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 1994; 35:1944-50.
27. 131I) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid. Radiother Oncol 1989; 14:35-41.
28. Loevinger R, Japha EM, Brownell GL. Discrete radioisotope sources. In:Hine GJ, Brownell GL, editors. Radiation dosimetry. New York: Academic Press, 1956:713-44.
29. 90Y. Radiother Oncol 1991; 21:91-9.
30. 131). J Clin Endocrinol Metab 1949; 9:1153-70.
31. 131I treatment of thyroid carcinoma. Br J Cancer 1973; 28:232-7.
32. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986; 59:45-51.
33. Pochin EE. Long term hazards of radioiodine treatment of thyroid carcinoma. In: Hedinger CE, editor. Thyroid cancer. New York: Springer-Verlag, 1969:293-304.
34. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F, et al. Outcome of 309 patients with metastatic differentiated thyroid cancer treated with radioiodine. World J Surg 1994; 18:600-4.